Lilly Profit Beats Analyst Estimates as Cymbalta Sales Climb

Eli Lilly & Co. reported fourth-quarter earnings that beat analyst estimates as sales of its top-selling drug, the Cymbalta depression treatment, increased 20 percent, helped by higher prices in the U.S.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.